Hikma Pharmaceuticals (LON:HIK - Get Free Report) had its target price boosted by research analysts at Jefferies Financial Group from GBX 1,870 to GBX 2,025 in a research report issued on Tuesday,London Stock Exchange reports. The brokerage currently has a "buy" rating on the stock. Jefferies Financial Group's price objective points to a potential upside of 24.00% from the company's previous close.
A number of other analysts also recently weighed in on HIK. Citigroup upped their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Berenberg Bank boosted their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a GBX 1,950 price target on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th. Six analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of GBX 2,085.83.
View Our Latest Analysis on HIK
Hikma Pharmaceuticals Stock Performance
Shares of LON:HIK opened at GBX 1,633 on Tuesday. Hikma Pharmaceuticals has a 12-month low of GBX 1,187 and a 12-month high of GBX 1,865. The stock has a market cap of £3.41 billion, a PE ratio of 9.02, a P/E/G ratio of 2.38 and a beta of 0.66. The business has a 50 day moving average of GBX 1,574.60 and a 200-day moving average of GBX 1,460.22. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57.
Insider Activity at Hikma Pharmaceuticals
In other Hikma Pharmaceuticals news, insider Tobias Hestler acquired 7,500 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of GBX 1,648 per share, for a total transaction of £123,600. Company insiders own 22.04% of the company's stock.
Hikma Pharmaceuticals Company Profile
(
Get Free Report)
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Hikma Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.
While Hikma Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
